COMMUNIQUÉS West-GlobeNewswire

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

12/12/2017 - 09:00

OXFORD, United Kingdom, Dec. 12, 2017 (GLOBE NEWSWIRE) -- PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors [...]

Operational Update

12/12/2017 - 07:55

SYDNEY, Australia, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (Immutep or the Company), has provided an update on the Company’s two ongoing clinical trials with eftilagimod alpha (LAG- [...]

NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES

12/12/2017 - 07:01

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES Company intends to continue preclinical development in this indication in 2018 [...]

NÉOVACS ANNONCE DES RÉSULTATS POSITIFS POUR SON ÉTUDE PRÉCLINIQUE AVEC l'IFNalpha KINOIDE DANS LE DIABÈTE DE TYPE 1

12/12/2017 - 07:01

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE NÉOVACS ANNONCE DES RÉSULTATS POSITIFS POUR SON ÉTUDE PRÉCLINIQUE AVEC l'IFNalpha KINOIDE DANS LE DIABÈTE DE TYPE 1 La société poursuivra ce [...]

INNATE PHARMA : UPCOMING INVESTOR CONFERENCES

12/12/2017 - 07:01

upcoming investor conferences Marseille, France, December 12, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor [...]

INNATE PHARMA : PROCHAINS RENDEZ-VOUS INVESTISSEURS

12/12/2017 - 07:01

PROCHAINS RENDEZ-VOUS INVESTISSEURS Marseille, le 12 décembre 2018 Innate Pharma SA (Euronext Paris: FR0010331421 - IPH) annonce aujourd'hui qu'elle sera présente aux événements suivants au cours du premier trimestre [...]

Final Preclinical Asthma Study Confirms Efficacy

12/12/2017 - 01:24

Clear confirmation of efficacy of Cynata’s proprietary Cymerus™ MSCs in second preclinical asthma study Treatment with Cymerus MSCs in clinically-relevant model caused significantly greater reduction of airway [...]

Stephanie Finnegan joins Cromos™ Pharma as Chief Operating Officer, company looks to expand its North American footprint

12/12/2017 - 00:10

PORTLAND, Ore., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Cromos™ Pharma , a premier regional contract research organization announced today that Stephanie Finnegan has been appointed as its Chief Operating Officer. Ms. [...]

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

12/12/2017 - 00:00

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing [...]

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

11/12/2017 - 23:19

LONDON, Dec. 11, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Enzymotec Shareholders Approve Proposed Acquisition by Frutarom

11/12/2017 - 23:15

MIGDAL HA’EMEQ, Israel, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY ) (“Enzymotec” or the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional [...]

Scythian Biosciences Corp. Announces Appointment of Ottis Anderson to Pro Athlete Advisory Committee

11/12/2017 - 23:07

TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the " Company " or “ Scythian ”) (TSXV:SCYB) (Frankfurt: 9SB ) (OTC Pink:SCCYF) is pleased to announce that it has appointed Ottis Jerome “O.J.” [...]

Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study

11/12/2017 - 22:46

PHILADELPHIA and OXFORD, United Kingdom, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study [...]

Karmanos Cancer Institute’s 24th Annual Partners Night continues to drive the future of cancer research

11/12/2017 - 22:34

DETROIT, Dec. 11, 2017 (GLOBE NEWSWIRE) -- When dedicated community members, including those touched by cancer, come together to support cancer research at Karmanos, it’s another way of describing the Barbara Ann [...]

Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial

11/12/2017 - 22:30

Trial investigators at City of Hope announce first-reported complete response from a CAR T therapy in a BPDCN patient, additional complete response achieved in AML Investigators found infusions of MB-102 are safe and [...]

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

11/12/2017 - 22:30

Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE [...]

Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting

11/12/2017 - 22:30

Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis City of Hope announces Mustang Bio’s MB- [...]

Minerva Neurosciences Names Richard Russell President

11/12/2017 - 22:30

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis

11/12/2017 - 22:21

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]